A detailed history of Pro Share Advisors LLC transactions in Arcutis Biotherapeutics, Inc. stock. As of the latest transaction made, Pro Share Advisors LLC holds 17,739 shares of ARQT stock, worth $164,972. This represents 0.0% of its overall portfolio holdings.

Number of Shares
17,739
Previous 20,990 15.49%
Holding current value
$164,972
Previous $208,000 21.15%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$7.24 - $12.53 $23,537 - $40,735
-3,251 Reduced 15.49%
17,739 $164,000
Q1 2024

May 08, 2024

BUY
$3.25 - $11.77 $6,077 - $22,009
1,870 Added 9.78%
20,990 $208,000
Q4 2023

Feb 14, 2024

BUY
$1.84 - $4.82 $15,478 - $40,545
8,412 Added 78.56%
19,120 $61,000
Q3 2023

Nov 13, 2023

BUY
$5.31 - $10.98 $249 - $516
47 Added 0.44%
10,708 $56,000
Q2 2023

Aug 10, 2023

BUY
$7.51 - $15.0 $80,064 - $159,915
10,661 New
10,661 $101,000
Q4 2022

Feb 02, 2023

BUY
$13.96 - $20.4 $144,890 - $211,731
10,379 New
10,379 $153,000
Q2 2022

Aug 01, 2022

SELL
$16.33 - $22.2 $169,848 - $230,902
-10,401 Closed
0 $0
Q1 2022

May 10, 2022

SELL
$14.38 - $22.79 $39,199 - $62,125
-2,726 Reduced 20.77%
10,401 $200,000
Q4 2021

Feb 08, 2022

SELL
$14.98 - $25.5 $17,197 - $29,274
-1,148 Reduced 8.04%
13,127 $272,000
Q3 2021

Nov 12, 2021

SELL
$19.28 - $27.1 $37,056 - $52,086
-1,922 Reduced 11.87%
14,275 $341,000
Q2 2021

Aug 13, 2021

BUY
$24.42 - $34.75 $74,944 - $106,647
3,069 Added 23.38%
16,197 $442,000
Q1 2021

May 14, 2021

BUY
$24.47 - $36.98 $44,266 - $66,896
1,809 Added 15.98%
13,128 $380,000
Q4 2020

Feb 09, 2021

BUY
$17.82 - $31.73 $201,704 - $359,151
11,319 New
11,319 $318,000

Others Institutions Holding ARQT

About Arcutis Biotherapeutics, Inc.


  • Ticker ARQT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 60,187,500
  • Market Cap $560M
  • Description
  • Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...
More about ARQT
Track This Portfolio

Track Pro Share Advisors LLC Portfolio

Follow Pro Share Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pro Share Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pro Share Advisors LLC with notifications on news.